Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Go back to Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 29.36 -0.16 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.52 | 52 Week High | $5.17 | |||
| Open | $30.24 | 52 Week Low | $0.94 | |||
| Day High | $30.54 | P/E | N/A | |||
| Day Low | $29.26 | EPS | $0.00 | |||
| Volume | 2,086,644 | |||||
